Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART
- PMID: 19629514
- DOI: 10.1007/s00417-009-1113-7
Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART
Abstract
Purpose: To evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.
Methods: The dry AMD treatment with Rheopheresis trial (ART) was a randomised, controlled clinical study. Patients with the diagnosis of AMD in both eyes, with the study eye presenting dry AMD and soft drusen (the fellow eye had advanced AMD) were randomly assigned in a 1:1 ratio to receive ten Rheopheresis treatments within 17 weeks or to remain untreated. The primary outcome was change in best-corrected ETDRS-visual acuity (mean logMar change) after 7.5 months compared to baseline visual acuity for both groups.
Results: Forty-three eyes of 43 patients (22 treatment and 21 control group) were analysed. The mean baseline BCVA in study eyes was 0.58 in the treatment group and 0.66 in the control group (n.s. p = 0.19). At the primary efficacy endpoint 7.5 months post baseline, there was a statistically significant mean difference of 0.95 ETDRS lines (p = 0.01) between the Rheopheresis and control groups. Nine percent of eyes in the group treated with Rheopheresis gained 2 or more ETDRS lines, as compared with 0% of eyes with no treatment. None of the treated patients had a loss in visual acuity in their study eyes, as compared with 24% of patients without treatment who lost 1 ETDRS line or more; 19% lost 2 ETDRS lines or more. Rheopheresis treatment was safe and well-tolerated.
Conclusion: The results of ART provide further evidence that Rheopheresis is a safe and effective therapeutic option for high-risk patients with dry AMD and no therapeutic alternative. A series of Rheopheresis treatments can improve the natural course of AMD for selected patients.
Similar articles
-
Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.Trans Am Ophthalmol Soc. 2002;100:85-106; discussion 106-7. Trans Am Ophthalmol Soc. 2002. PMID: 12545682 Free PMC article. Clinical Trial.
-
RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration.Ther Apher Dial. 2010 Jun;14(3):276-86. doi: 10.1111/j.1744-9987.2010.00807.x. Ther Apher Dial. 2010. PMID: 20609179
-
Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results.Trans Am Ophthalmol Soc. 2006;104:221-31. Trans Am Ophthalmol Soc. 2006. PMID: 17471343 Free PMC article. Clinical Trial.
-
Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD).J Clin Apher. 2005 Oct;20(3):185-94. doi: 10.1002/jca.20047. J Clin Apher. 2005. PMID: 15892078 Review.
-
Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine.Transfus Apher Sci. 2003 Aug;29(1):71-84. doi: 10.1016/S1473-0502(03)00101-0. Transfus Apher Sci. 2003. PMID: 12877897 Review.
Cited by
-
Dynamics of blood count after rheohemapheresis in age-related macular degeneration: possible association with clinical changes.Biomed Res Int. 2014;2014:858219. doi: 10.1155/2014/858219. Epub 2014 Mar 6. Biomed Res Int. 2014. PMID: 24734249 Free PMC article.
-
Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide.Clin Ophthalmol. 2019 Feb 1;13:233-241. doi: 10.2147/OPTH.S188315. eCollection 2019. Clin Ophthalmol. 2019. PMID: 30774304 Free PMC article.
-
A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits.Molecules. 2020 Feb 4;25(3):663. doi: 10.3390/molecules25030663. Molecules. 2020. PMID: 32033125 Free PMC article.
-
Potential Use of Plasma Rich in Growth Factors in Age-Related Macular Degeneration: Evidence from a Mouse Model.Medicina (Kaunas). 2024 Dec 10;60(12):2036. doi: 10.3390/medicina60122036. Medicina (Kaunas). 2024. PMID: 39768916 Free PMC article.
-
Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration: A PRISMA-compliant network meta-analysis of randomized controlled trials.Medicine (Baltimore). 2018 May;97(21):e10422. doi: 10.1097/MD.0000000000010422. Medicine (Baltimore). 2018. PMID: 29794727 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous